文献速递造血干细胞移植与细胞治疗

靶向CDC42减轻造血干细胞移植后的骨骼退变

Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2024-01-01

该研究在小鼠及人类造血干细胞移植(HSCT)模型中观察间充质干/祖细胞(MSPC)功能与骨骼变化,发现移植后MSPC集落形成能力下降、DNA损伤增加、衰老增强且骨体积减少,与CDC42活性升高、F-肌动蛋白分布紊乱、线粒体异常及线粒体自噬受损相关;药物抑制CDC42可体外恢复MSPC功能,体内靶向CDC42可提高MSPC质量并增加骨体积与骨小梁厚度。

要点

  • HSCT后小鼠MSPC成纤维细胞集落形成单位频率降低、DNA损伤增加、细胞衰老增强,且骨体积减少。
  • MSPC功能下降与CDC42活性升高、F-肌动蛋白分布紊乱、线粒体异常及线粒体自噬受损相关。
  • 体内靶向CDC42活性可改善移植动物MSPC质量,增加骨体积和骨小梁厚度。

核心结论

  • 减轻CDC42活性足以减轻骨髓移植背景下MSPC功能的降低。

研究设计与样本

  • 研究检测了接受HSCT的小鼠及接受HSCT人类的间充质干/祖细胞(MSPC),并在体外和体内进行CDC42靶向干预。

主要发现

  • 接受HSCT的小鼠MSPC显示成纤维细胞集落形成单位频率降低、DNA损伤增加、细胞衰老发生增强,同时接受HSCT的动物骨体积减少。
  • MSPC功能降低与CDC42活化升高、F-肌动蛋白分布紊乱、线粒体异常及MSPC线粒体自噬受损相关。
  • 接受HSCT人类的MSPC也观察到与小鼠相似的变化和缺陷。
  • 体外药物处理减轻CDC42活化升高后,恢复了MSPC的F-肌动蛋白纤维排列、线粒体功能和线粒体自噬。
  • 体内靶向接受移植动物的CDC42活性改善了MSPC质量,增加了骨体积和骨小梁厚度。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteopenia and osteoporosis are common long-term complications of the cytotoxic conditioning regimen for hematopoietic stem cell transplantation (HSCT). We examined mesenchymal stem and progenitor cells (MSPCs), which include skeletal progenitors, from mice undergoing HSCT. Such MSPCs showed reduced fibroblastic colony-forming units frequency, increased DNA damage, and enhanced occurrence of cellular senescence, whereas there was a reduced bone volume in animals that underwent HSCT. This reduced MSPC function correlated with elevated activation of the small Rho guanosine triphosphate hydrolase CDC42, disorganized F-actin distribution, mitochondrial abnormalities, and impaired mitophagy in MSPCs. Changes and defects similar to those in mice were also observed in MSPCs from humans undergoing HSCT. A pharmacological treatment that attenuated the elevated activation of CDC42 restored F-actin fiber alignment, mitochondrial function, and mitophagy in MSPCs in vitro. Finally, targeting CDC42 activity in vivo in animals undergoing transplants improved MSPC quality to increase both bone volume and trabecular bone thickness. Our study shows that attenuation of CDC42 activity is sufficient to attenuate reduced function of MSPCs in a BM transplant setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Landspersky T, Stein M, Saçma M, et al. Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantation. Blood Adv. 2024. PMID: 39159429. doi:10.1182/bloodadvances.2024012879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。